simlukafusp alfa + atezolizumab + bevacizumab

**simlukafusp alfa + atezolizumab + bevacizumab** is a triple-combination therapy under clinical investigation for advanced solid tumors and selected cancers. Simlukafusp alfa (FAP-IL2v) is a recombinant fusion protein targeting fibroblast activation protein (FAP) and engineered interleukin-2 variant (IL2v), designed to activate immune effector cells (CD8+ T cells and NK cells) within the tumor microenvironment without activating regulatory T cells. Atezolizumab is a humanized monoclonal antibody that blocks programmed death-ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor. Bevacizumab is a monoclonal antibody against vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis. This regimen aims to synergistically enhance antitumor immunity by combining T-cell activation, checkpoint inhibition, and suppression of tumor vasculature. The combination has shown the ability to expand and activate peripheral immune effectors and to improve antitumor effects in preclinical models and early-phase clinical studies for advanced solid tumors, with ongoing clinical trials[1][3].

Other names

simlukafusp alfa + atezolizumab + bevacizumabFAP-IL2v + atezolizumab + bevacizumab